Breakthrough pancreatic cancer treatment could double survival time‎

A new study on a groundbreaking pancreatic cancer drug finds that it has the potential to double survival rates for more than 90 percent of patients. Researchers are now exploring whether the drug, called daraxonrasib, could also be effective in lung, ovarian, and colorectal cancers. NBC News’ Erika Edwards reports.